A retrospective study sought to determine if treatment of myeloproliferative neoplasms with ruxolitinib may have nephroprotective effects.
Hematology nurse navigators provide patients with blood cancer with consistency in the midst of a storm, advocacy in chaos, direction when all seems lost, and most importantly, hope.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Postinduction, median nadir serum asparaginase activity was similar in patients receiving either drug, suggesting a need for dosing optimization.
[Cancer Management and Research] A review of data from clinical trials on the use of carfilzomib, a second-generation PI, in the treatment of R/R multiple myeloma, as well as ongoing studies and prescribing advice.